Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
AKBA's Cash to Debt is ranked higher than
72% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AKBA' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
AKBA's Interest Coverage is ranked higher than
61% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 16.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -48.58
AKBA's ROE (%) is ranked lower than
62% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. AKBA: -48.58 )
Ranked among companies with meaningful ROE (%) only.
AKBA' s ROE (%) Range Over the Past 10 Years
Min: -51.66  Med: -51.66 Max: -51.66
Current: -48.58
ROA (%) -45.13
AKBA's ROA (%) is ranked lower than
66% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. AKBA: -45.13 )
Ranked among companies with meaningful ROA (%) only.
AKBA' s ROA (%) Range Over the Past 10 Years
Min: -71.35  Med: -50.85 Max: -47.82
Current: -45.13
-71.35
-47.82
ROC (Joel Greenblatt) (%) -15143.53
AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. AKBA: -15143.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKBA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -106220  Med: -31616.67 Max: -16403.47
Current: -15143.53
-106220
-16403.47
» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AKBA Guru Trades in

Q2 2015

AKBA Guru Trades in Q2 2015

Jim Simons 381,239 sh (New)
» More
Q3 2015

AKBA Guru Trades in Q3 2015

Jim Simons 110,700 sh (-70.96%)
» More
Q4 2015

AKBA Guru Trades in Q4 2015

Steven Cohen 42,000 sh (New)
Jim Simons 109,200 sh (-1.36%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
AKBA's P/B is ranked higher than
68% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. AKBA: 2.20 )
Ranked among companies with meaningful P/B only.
AKBA' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 9.5
Current: 2.2
0
9.5
Current Ratio 11.88
AKBA's Current Ratio is ranked higher than
80% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. AKBA: 11.88 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 10.23 Max: 16.05
Current: 11.88
0.46
16.05
Quick Ratio 11.88
AKBA's Quick Ratio is ranked higher than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. AKBA: 11.88 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 10.23 Max: 16.05
Current: 11.88
0.46
16.05

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.28
AKBA's Price/Net Cash is ranked higher than
81% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. AKBA: 2.28 )
Ranked among companies with meaningful Price/Net Cash only.
AKBA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.32  Med: 2.73 Max: 3.13
Current: 2.28
2.32
3.13
Price/Net Current Asset Value 2.24
AKBA's Price/Net Current Asset Value is ranked higher than
82% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. AKBA: 2.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AKBA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.29  Med: 2.68 Max: 3.07
Current: 2.24
2.29
3.07
Price/Tangible Book 2.20
AKBA's Price/Tangible Book is ranked higher than
74% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. AKBA: 2.20 )
Ranked among companies with meaningful Price/Tangible Book only.
AKBA' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.28  Med: 2.65 Max: 3.02
Current: 2.2
2.28
3.02
Earnings Yield (Greenblatt) (%) -28.15
AKBA's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. AKBA: -28.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKBA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -113.4  Med: 0.00 Max: 0
Current: -28.15
-113.4
0

More Statistics

EPS $ -2.26
Short Percentage of Float7.60%
52-Week Range $5.91 - 14.20
Shares Outstanding(Mil)37.94

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 20 50 66
EPS($) -2.32 -2.62 -2.67
EPS without NRI($) -2.32 -2.62 -2.67

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ASND, LSE:PRTC, NAS:ESPR, NAS:TRVN, NAS:MRTX, BOM:532526 » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National... Apr 26 2016
Increased Earnings Estimates Seen for Akebia Therapeutics (AKBA): Can It Move Higher? Apr 13 2016
Akebia Therapeutics (AKBA): Strong Industry, Solid Earnings Estimate Revisions Apr 05 2016
Akebia to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Akebia to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
AKEBIA THERAPEUTICS, INC. Financials Mar 18 2016
Akebia Therapeutics (AKBA) Stock Down on Q4 Results Mar 15 2016
Edited Transcript of AKBA earnings conference call or presentation 14-Mar-16 8:30pm GMT Mar 15 2016
Akebia Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today Mar 14 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 14 2016
Akebia Therapeutics reports 4Q loss Mar 14 2016
Akebia Therapeutics reports 4Q loss Mar 14 2016
Akebia Announces Fourth Quarter and Full-Year 2015 Financial Results Mar 14 2016
Q4 2015 Akebia Therapeutics Inc Earnings Release - Before Market Open Mar 14 2016
5 Stocks Under $10 Set to Soar Higher Mar 10 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 09 2016
Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat Mar 09 2016
Akebia to Host Conference Call on March 14th to Discuss Full-Year 2015 Financial Results and... Mar 08 2016
Akebia to Present at the 18th Annual BIO CEO & Investor Conference Feb 01 2016
Akebia to Present at the 18th Annual BIO CEO & Investor Conference Feb 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK